This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Captopril

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 13: Line 13:
===Pharmacokinetics===
===Pharmacokinetics===
-
{| class="wikitable" border="1" width="50%" style="text-align:center"
+
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%">
-
|-
+
<tr>
-
! colspan="8" align="center"| ACE-Inhibitor [[Pharmacokinetics]] Comparison at Equivalent Dosages <ref>PMID: 7867683</ref><ref>DOI: 10.1111/j.1365-2710.2005.00646.x</ref><ref>PMID: 16075412</ref><ref>PMID:7527101</ref>
+
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset">
-
|-
+
<div style="height:100%; width: 100%">
-
! Parameter
+
{{:ACE Inhibitor Pharmacokinetics}}
-
! [[Captopril]]
+
</div>
-
! [[Lisinopril]]
+
</td>
-
! [[Ramipril]]
+
</tr>
-
! [[Enalapril]]
+
</table>
-
! [[Benazepril]]
+
 
-
! [[Perindopril]]
+
-
! [[Trandolapril]]
+
-
|-
+
-
! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
+
-
! .98
+
-
! 6.5
+
-
! .67
+
-
! 1.06
+
-
! .5
+
-
! .75
+
-
! .72
+
-
|-
+
-
! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
+
-
! 1210
+
-
! 79
+
-
! 16.4
+
-
! 314
+
-
! 149
+
-
! 105
+
-
! 1.68
+
-
|-
+
-
! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
+
-
! 72
+
-
! 25
+
-
! 28
+
-
! 60
+
-
! 97
+
-
! 24
+
-
! 10
+
-
|-
+
-
! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
+
-
! 97
+
-
! 0
+
-
! 73
+
-
! 20
+
-
! 97
+
-
! 20
+
-
! 80
+
-
|-
+
-
! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
+
-
! .56
+
-
! 10.1
+
-
! 1.93
+
-
! 1.6
+
-
! 10
+
-
! .9
+
-
! .68
+
-
|-
+
-
! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
+
-
! 1673
+
-
! 1016
+
-
! 21.9
+
-
! 450
+
-
! 140
+
-
! 182
+
-
! 1.86
+
-
|-
+
-
! [[Pharmacokinetics#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM)
+
-
! 1.1
+
-
! 5.5
+
-
! 5.0
+
-
! 5.4
+
-
! 1.7
+
-
! 2.4
+
-
! 2.5
+
-
|-
+
-
! Dosage (mg)
+
-
! 10
+
-
! 20
+
-
! 5
+
-
! 20
+
-
! 10
+
-
! 4
+
-
! 2
+
-
|-
+
-
! Metabolism
+
-
! Hepatic (CYP2D6)
+
-
! None
+
-
! Hepatic
+
-
! Hepatic (CYP3A4)
+
-
! Hepatic
+
-
! Hepatic
+
-
! Hepatic (CYP2D6 & CYP2C9)
+
-
|}
+
==References==
==References==

Revision as of 09:14, 10 December 2010

Captopril, also known as Capoten

Drag the structure with the mouse to rotate

Better Known as: Capoten

Mechanism of Action

Extensive research has validated a pathological role for Angiotensin II in cardiac, renal and vascular diseases. [1] Bradykinin, a small peptide that counterbalance the effects of Angiotensin II by acting as a strong vasodilator upon binding AT2, is degraded by the same ACE-1 enzyme. Since ACE-1 is the primary producer of Angiotensin II and primary degrader of Bradykinins, inhibition of ACE-1 has proven an effective treatment for Hypertension and Congestive Heart Failure. Captopril binds to the ACE-1 binding site of , preventing ACE-1 from binding angiotensin. Captopril,, forming electrostatic interactions with His 353, Glu 384, Lys 511, His 513 and Tyr 520, along with zinc cation. [2]

Pharmacokinetics

ACE-Inhibitor Pharmacokinetics Comparison at Equivalent Dosages
Parameter Captopril Lisinopril Ramipril Enalapril Benazepril Perindopril Trandolapril
Tmax (hr) .98 6.5 .67 1.06 .5 .75 .72
Cmax (ng/ml) 1210 79 16.4 314 149 105 1.68
Bioavailability (%) 72 25 28 60 97 24 10
Protein Binding (%) 97 0 73 20 97 20 80
T1/2 (hr) .56 10.1 1.93 1.6 10 .9 .68
AUC (ng/ml/hr) 1673 1016 21.9 450 140 182 1.86
IC50 (nM) 1.1 5.5 5.0 5.4 1.7 2.4 2.5
Dosage (mg) 10 20 5 20 10 4 2
Metabolism Hepatic (CYP2D6) None Hepatic Hepatic (CYP3A4) Hepatic Hepatic Hepatic (CYP2D6 & CYP2C9)

For Pharmacokinetic Data References, See: References


References

  1. ↑ Ferrario CM. Role of angiotensin II in cardiovascular disease therapeutic implications of more than a century of research. J Renin Angiotensin Aldosterone Syst. 2006 Mar;7(1):3-14. PMID:17083068
  2. ↑ Natesh R, Schwager SL, Evans HR, Sturrock ED, Acharya KR. Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme. Biochemistry. 2004 Jul 13;43(27):8718-24. PMID:15236580 doi:10.1021/bi049480n


Proteopedia Page Contributors and Editors (what is this?)

David Canner, Alexander Berchansky

Retrieved from "http://52.214.119.220/wiki/index.php/Captopril"
Personal tools